From funding to future access: Why early value planning matters in drug development

Investors and future partners want to understand what happens if the science succeeds. Is there a clear market opportunity? Can the asset demonstrate meaningful value, secure reimbursement, and reach the right patients? Early value planning brings these questions into development sooner, while there is still time to act on the answers.

Science alone does not tell the whole investment story

A compelling mechanism of action, encouraging data, and a clear clinical plan are essential. But they only tell part of the story. Investors also need to understand the asset’s potential place in the market, the evidence required to support access, and how it could differentiate from the standard of care. Identifying possible reimbursement and adoption barriers early gives teams more time to address them.

These are not launch-stage questions. Indication selection, target populations, comparators, endpoints, and evidence plans can all shape future value. By the time an asset is approaching commercialization, many of those decisions are difficult, costly, or impossible to revisit.

The goal is not to predict every market condition years in advance. It is to establish a clear decision logic: what must be true for the asset to succeed, what evidence will test those assumptions, and when the strategy should be refined.

What investors need to see

Investment decisions increasingly weigh commercial viability alongside scientific potential. A credible asset story should demonstrate a clear understanding of:

• Unmet need and patients most likely to benefit
• Potential position in an evolving treatment landscape
• Outcomes that matter to regulators, payers, health technology assessment bodies, clinicians, and patients
• Evidence needed to support differentiation and reimbursement
• Assumptions informing pricing potential, launch sequencing, and geographic expansion
• Access risks that could limit uptake following approval

Uncertainty will always be part of drug development. Defining it clearly and showing how the company plans to address it gives investors greater confidence in both the asset and the decisions ahead.

Value planning needs to start earlier

Early-stage companies need to prioritize clinical progress and use capital carefully. But when development is planned only around regulatory milestones, teams can overlook evidence that will eventually shape pricing, reimbursement, and access. The evidence required for approval may not be enough to demonstrate value to payers and health technology assessment bodies.

Relevant comparators, meaningful outcomes, resource use, and uncertainty within specific patient populations can all influence access decisions. Considering these requirements while the development plan is still flexible gives teams more opportunity to address evidence gaps before they become difficult or costly to resolve.

What should early value planning in drug development address?

• Market access and reimbursement pathways in priority markets
• Current and future comparators, including the likely standard of care at launch
• Clinical, patient-reported, real-world, and health economic evidence needs
• Value proposition for different decision-makers
• Early price potential and the evidence needed to defend it
• Key risks, decision points, and triggers for changing course

The result should be a living strategy, not a one-time deliverable. As the data, competitive landscape, and policy environment evolve, the value story and evidence plan should evolve with them.

Early planning leads to better decisions

Considering market access during development gives leadership a stronger basis for making choices about the asset, where to invest, and when the strategy needs to change.

1. Connect development choices to future value

Early planning helps teams understand how development decisions could affect the asset’s eventual market position. This creates greater alignment across clinical, commercial, and market access teams before priorities and resources are committed.

2. Build a more credible case for differentiation

A strong value story explains more than how a therapy is innovative. It shows where the asset could make a meaningful difference in treatment or care. Defining that position early gives investors and potential partners a clearer reason to believe in the opportunity.

3. Preserve room to respond

Market conditions, competitors, and pricing expectations will continue to change as an asset advances. Identifying the assumptions most likely to affect success lets leadership monitor them and adjust course before options become limited.

The role of the right strategic partner

Emerging biopharma companies do not need to build every capability in-house. A strategic partner can provide senior market access, pricing, evidence, and commercial expertise as those needs arise during development.

The right partner also brings experience across markets and development programs, helping teams challenge internal assumptions and anticipate how different decision-makers may evaluate the asset. For companies managing limited time, resources, and internal capacity, that outside perspective can strengthen key decisions without adding unnecessary infrastructure.

At Acumetis, our experts work alongside client teams from early strategy through execution, providing practical guidance and senior accountability at each stage.

Prepare for diligence beyond the current funding round

The next investor, strategic or licensing partner, potential acquirer, or commercialization partner will test the assumptions behind the asset. They will examine the market opportunity, evidence plan, pricing and reimbursement potential, competitive position, and opportunities for expansion into additional markets or indications.

Companies that address these questions early enter diligence with evidence rather than assumptions. They are better prepared to explain where the asset can create value, what risks remain, and how the development strategy is designed to address them.

Early value planning cannot eliminate uncertainty, but it can make an asset’s path from scientific promise to investment, reimbursement, and patient access far more credible.

Connect science, investment, and access

Drug development is stronger when science, evidence, investment, and access are considered together. 

Early value planning in drug development gives teams a clearer view of the decisions ahead and helps ensure that the evidence generated along the way supports not only approval, but also differentiation, reimbursement, and patient access.

Get in touch with our team to learn more.